1. Background {#sec1}
=============

In the era of highly active antiretroviral therapy (HAART), liver diseases have become one of the commonest nonacquired immune deficiency syndrome (AIDS) related causes of death. It accounts for 14--18% of mortalities among human immunodeficiency virus (HIV) infected patients \[[@B1], [@B2]\]. Among hospitalized HIV patients on HAART, almost half of deaths are attributed to liver diseases which range from asymptomatic or mild elevations of liver enzymes to cirrhosis, end stage liver disease, and other associated complications \[[@B3], [@B4]\]. Most of the studies have linked these abnormalities to hepatotoxicity caused by antiretroviral drugs without considering other factors such as HIV viral load and viral hepatitis among many others that can potentially cause abnormalities of the liver enzymes \[[@B5]--[@B7]\]. Several factors may be involved in these patients making it difficult to clearly establish the etiology. Concomitant infections with viral hepatitis such as hepatitis B (HBV) and hepatitis C (HCV), other opportunistic infections, alcohol abuse, AIDS related malignancies, and many other entities might be associated with abnormality of liver enzymes \[[@B8]--[@B10]\]. However, epidemiology and distribution of these factors might differ from different geographical locations with limited reports from low- and middle-income countries. This study aimed at determining factors associated with liver enzyme abnormalities among HIV population attending different centers in the Lake Victoria zone, Tanzania. The findings from this study might help the health care providers to establish proper monitoring and management of HIV infected individuals by increasing awareness about other factors that can contribute to the abnormalities of liver enzymes in this population.

2. Methods {#sec2}
==========

2.1. Study Design, Area, and Period {#sec2.1}
-----------------------------------

This was a cross-sectional hospital based study which was conducted in July 2017 at the Bugando Medical Centre (BMC). BMC is a consultant and teaching hospital with about 900 bed capacity located in the Northwestern of Tanzania serving the lake zone regions, namely, Mwanza, Mara, Kagera, Shinyanga, Simiyu, and Kigoma with estimated population size of thirteen million people. BMC process samples for viral load for all CTCs in the lake zone and in each day samples from all centers are received.

2.2. Sample Size Estimation, Study Population, Sampling, and Selection Criteria {#sec2.2}
-------------------------------------------------------------------------------

Sample size was estimated by using Kish Leslie formula using the prevalence of 16.4% \[[@B11]\]; the minimum sample size was 211 sera. However, a total of 230 samples were collected. All blood samples collected from different care and treatment centers (CTCs) in different regions for viral load testing at BMC were eligible to be included in the study. Samples with required variables/parameters (age, sex, residence, ART regimen (first, second, or third line), reason for HIV viral load testing (first test, repeating test, or suspected treatment failure), and drug adherence) were serially included until the required sample size was reached.

2.3. Data Collection Procedure {#sec2.3}
------------------------------

Sociodemographic and other relevant information such as age, sex, residence, ART regimen (first, second, or third line), reason for HIV viral load testing (first test, repeating test, or suspected treatment failure), and drug adherence (good, fair, or poor) were extracted from laboratory request forms accompanying samples for viral load testing using a checklist. Blood specimens in vacutainer EDTA tubes (BD, Franklin Lakes, New Jersey, USA) collected from different CTCs in different regions for viral load testing at BMC were used in this study.

2.4. Laboratory Procedures {#sec2.4}
--------------------------

EDTA blood samples were centrifuged at 4000 revolutions per minute for 20 minutes to obtain plasma which was then used for viral load testing. Viral load testing was done using a COBAS TaqMan analyzer (Roche diagnostics, Germany) following the manufacturer\'s instructions. Viral suppression was defined as viral load \< 1000 copies/mL \[[@B12]\].

The liver enzymes (ASAT and ALAT) were analyzed using the CIBA CORNING 252 calorimeter (Ciba Corning Analytical Halstead, England). Liver enzymes were considered normal when values range from 2-40 IU/mL for ASAT and 2-41IU/mL for ALAT. In addition, all samples were analyzed for the presence of HBV antigens and HCV antibodies using immunochromatographic tests (Wondfo HBsAg and HCV antibodies, Guangzhou, China) following the manufacturer\'s instructions.

2.5. Quality Control {#sec2.5}
--------------------

The standard operating procedures were strictly followed for the quality assurance. Control materials with known ALAT and ASAT results were used to calibrate the calorimeter as per assay kit instructions before processing the samples for ASAT and ALAT. HBV and HCV kits were quality checked using known HBsAg and anti-HCV antibody positive and negative sera controls.

2.6. Data Management and Analysis {#sec2.6}
---------------------------------

Every sample was given a unique identification number. All data were recorded in the log book, transferred to excel then transferred to STATA version 13 (San Antonio, Texas) for cleaning and analysis. Results were presented into proportions for categorical variables and median (IQR) for continuous variables. Chi square test was used to test the association between liver enzymes abnormalities and other factors such as viral hepatitis and HIV viral load followed by multivariate logistic regression analysis to establish independent predictors. Wilcoxon Rank Sum Mann--Whitney test was used to compare median for various groups. A P value of \< 0.05 at 95% confidence interval was considered statistically significant.

2.7. Ethical Considerations {#sec2.7}
---------------------------

Ethical clearance for using patient\'s samples was sought from the joint CUHAS/BMC research ethics and review committee with ethical clearance number CREC/381/2017. Permission to conduct the study was requested from hospital laboratory administration. All patient-related information was stored carefully and anonymously using codes.

3. Results {#sec3}
==========

3.1. Sociodemographic and Clinical Data of the Participants {#sec3.1}
-----------------------------------------------------------

A total of 230 HIV seropositive individuals on ART with the median age of 33 (IQR: 30-48) years participated in this study. The slight majority of the participants 152 (66.1%) were females. A significant proportion of them were from Shinyanga (30.43%), Bunda (26.5%), and Butiama (21.3%). Other characteristics are shown in [Table 1](#tab1){ref-type="table"}. The median age of participants with high ASAT levels was 24(IQR: 15-41) years while that of those with high ALAT levels was 33(IQR: 22-41) years. On Wilcoxon Rank Sum Mann--Whitney test, there was no significant difference on age among participants with high ASAT levels compared to their counterparts \[38(IQR: 29.5-47) vs. 38(IQR: 30-48) years, P=0.577\] while the median age of participants with high ALAT levels was significantly low compared to their counterparts \[33(IQR: 27-43) vs. 39(IQR: 30-49), P=0.036\].

3.2. Prevalence of Liver Enzyme Abnormalities and Associated Factors among HIV Infected Patients {#sec3.2}
------------------------------------------------------------------------------------------------

Overall, the prevalence of liver enzyme abnormalities was 43.04% (99/230, 95% CI: 36.6-49.3). A total of 60 patients (26.09%) had elevated ASAT level while 55 patients (23.9%) had elevated ALAT levels ([Table 1](#tab1){ref-type="table"}). Regarding ASAT levels, on univariate analysis high HIV viral load (P=0.001), coinfection with HBV (P\<0.001), and HCV (P=0.017) were significantly associated with elevated ASAT levels. Only high HIV viral load (OR: 2.86, 95% CI:1.45-5.65, P=0.002) was independently found to predict high levels of ASAT ([Table 2](#tab2){ref-type="table"}). On the other side coinfection with HCV was significantly associated with elevated ALAT levels (P=0.017) on univariate analysis while none of the factors was found to predict ALAT levels on multivariate logistic regression analysis ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

Liver enzyme abnormalities are common among human immunodeficiency virus (HIV) infected individuals and have been associated with multiple factors. However, the risk factors associated with these abnormalities tend to differ in different geographical locations. To the best of our knowledge, this is the first study to investigate factors associated with liver enzyme abnormalities in the Lake Victoria zone, Tanzania. The most salient finding in this study is high overall prevalence of liver enzyme abnormalities which was observed to be 43.09%. This was significantly high in comparison to previous studies in Cameroon and South Africa which observed the prevalence of (22%) and (23%), respectively \[[@B13], [@B14]\]. Furthermore, in comparison with a previous study in Rwanda \[[@B11]\] in East Africa, the prevalence reported in this study is indeed significantly high. These variations could be explained by genetic variations in metabolizing antiretroviral drugs which may affect the drug toxicity. In addition, elevated liver enzymes in HIV infected patients might be due to direct inflammation of hepatocytes by HIV virus through apoptosis, mitochondrial dysfunction, and permeability alteration in mitochondrial membrane that stimulates an inflammatory response \[[@B15]\]. This has been further confirmed in this study whereby liver enzyme abnormalities were significantly associated with high HIV viral load.

In this study, liver enzyme abnormalities were found to be significantly associated with viral hepatitis (HBV and HCV); this observation was similar to the previous studies \[[@B13], [@B16]--[@B19]\]. In addition, Cicconi et al. observed high levels of liver enzyme abnormalities among HIV-viral hepatitis coinfected patients than HIV monoinfected patients \[[@B20]\]. The possible explanation could be viral cytopathic effects \[[@B21]\]. Further studies to investigate the HBV and HCV viral load in relation to liver enzymes abnormalities in HIV infected patients are of paramount importance.

Another observation in this study was significant association between high ALAT levels with young age. This could be explained by the fact that young aged individuals can mount strong immunity than old aged individuals; therefore, the elevated ALAT could be associated with immunopathology following viral infections \[[@B22]\].

5. Limitation of the Study {#sec5}
==========================

One of the major limitations of this study could be the sensitivity of the assays which might affect the results. In addition, other factors that can cause liver damage such as alcohol abuse and opportunistic infections were not investigated.

6. Conclusion {#sec6}
=============

This study observed high prevalence of liver enzyme abnormalities which was significantly associated with viral hepatitis and high HIV viral load among HIV infected patients in the Lake Victoria zone, Tanzania. Therefore, monitoring and management of liver enzymes abnormalities in HIV infected patients are essential in this setting.
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###### 

Demographic and clinical characteristics of HIV positive individuals in the lake zone (N=230).

  Variables              Categories          Frequency (n)   Percent
  ---------------------- ------------------- --------------- ---------
  *Age∗*                                     37.35(1-75)      
                                                             
  *Sex*                  Female              152             66.09%
  Male                   78                  33.91%          
                                                             
  *ART Regimen*          1g-A(TDF+3TC+EFV)   111             48.26
  1b-A(AZT+3TC+NVP)      40                  17.39           
  2H-A(TDF+FTC+ATV/R)    5                   2.17            
  2s-A (AZT+3TC+ATV/R)   1                   0.43            
  Ic-P(AZT+3TC+EFV)      4                   1.74            
                                                             
  *ASAT*                 Normal              170             73.91
  High                   60                  26.09           
                                                             
  *ALAT*                 Normal              175             76.09
  High                   55                  23.91           
                                                             
  Age*∗*                 High ASAT           24(15-41)        
  High ALAT              33(22-41)                           

**∗**: age (in years) in median (IQR).

*AZT* = Zidovudine, *EFV* = Efavirenz, *R* = Ritonavir, *NVP* = Nevirapine, *TDF*= Tenofovir, *3TC* = Lamivudine, *ATV* = Atazanavir, *FTC* = Emtricitabine.

###### 

Factors associated with high ASAT levels among HIV positive individual in the lake zone (N=230).

                                 Univariate analysis   Multivariate analysis                                           
  ---------------- ------------- --------------------- ----------------------- ------------------- ------------------- -------
                                 n(% )                 n(%)                                                             
                                                                                                                       
  Age*∗*                                               70(56-96)                                   0.99\[0.96-1.01\]   0.514
                                                                                                                       
  Sex              Female        115(75.66)            37(24.34)                                                        
  Male             55(70.51)     23(29.49)             0.400                                                           
                                                                                                                       
  IgA              No            84(70.59)             35(29.41)               0.234                                    
  Yes              86(77.48)     25(23.52)                                                                             
                                                                                                                       
  IbA              No            145(76.32)            45(26.68)                                                        
  Yes              25(62.50)     15(37.50)             0.071                   1.4(0.6-3.5)        0.367               
                                                                                                                       
  IcA              No            138(73.80)            49(26.20)               0.933                                    
  Yes              32(74.42)     11(25.58)                                                                             
                                                                                                                       
  IeA              No            144(73.10)            53(23.90)               0.491                                    
  Yes              26(78.79)     7(21.21)                                                                              
                                                                                                                       
  Adherence        Good          87(79.09)             23(20.01)                                                        
  Poor             83(69.87)     37(30.83)             0.087                   1.39\[0.68-2.80\]   0.357               
                                                                                                                       
  Viral load       Suppression   126(80.25)            31(19.75)                                                        
  No suppression   44(60.27)     29(39.73)             *0.001∗∗*               2.86\[1.45-5.65\]   *0.002∗∗*           
                                                                                                                       
  HBV              Negative      170(77.98)            48(22.02)                                                        
  Positive         0(0.00)       12(100)               *\<0.001∗∗*                                                     
                                                                                                                       
  HCV              Negative      170(74.56)            58(25.44)                                                        
  Positive         0(0.00)       2(100)                *0.017∗∗*                                                       

*∗*: age (in years) in Median (IQR).

*∗∗*: significant association.

###### 

Factors associated with high ALAT levels among HIV positive individual in the lake zone (N=230).

                                                                         Univariate regression   Multivariate regression                                           
  ------------------------------------ --------------------------------- ----------------------- ------------------------- ------------------- ------------------- -------
                                                                         *n(%)*                  *n(%)*                                                             
                                                                                                                                                                   
  Age*∗*                                                                                         78(67-98)                                     0.98\[0.96-1.00\]   0.171
                                                                                                                                                                   
  Sex                                  *Female*                          116(76.32)              36(26.68)                 0.910                                    
  *Male*                               59(75.64)                         19(25.36)                                                                                 
                                                                                                                                                                   
  IgA                                  No                                91(76.47)               28(23.53)                                                          
  Yes                                  84(75.68)                         27(25.32)               0.888                                                             
                                                                                                                                                                   
  IbA                                  No                                144(75.79)              46(24.21)                 0.818                                    
  Yes                                  31(77.50)                         9(22.50)                                                                                  
                                                                                                                                                                   
  IcA                                  No                                142(75.94)              45(24.06)                 0.911                                    
  Yes                                  33(76.74)                         10(23.26)                                                                                 
                                                                                                                                                                   
  IeA                                  No                                151(76.65)              46(23.35)                                                          
  Yes                                  24(72.73)                         9(27.27)                0.625                                                             
                                                                                                                                                                   
  Adherence                            Good                              89(80.91)               21(19.09)                                                          
                                                                                                                                                                   
                                       Poor                              86(71.67)               34(28.33)                 0.101               1.61\[0.81-3.18\]   0.170
                                                                                                                                                                   
  Viral                                Suppression (\<1,000 copies/mL)   125(79.62)              32(20.68)                                                          
  No suppression (≥ 1,000 copies/mL)   50(68.49)                         23(31.51)               0.066                     1.75\[0.88-3.49\]   0.107               
                                                                                                                                                                   
  HBV                                  Negative                          171(78.44)              47(21.56)                                                          
  Positive                             4(33.33)                          8(66.67)                                                                                  
                                                                                                                                                                   
  HCV                                  Negative                          170(74.56)              58(25.44)                                                          
  Positive                             0(0.00)                           2(100)                  *0.017∗∗*                                                         

*∗*: age (in years) in Median (IQR).

*∗∗*: significant association.
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